HCPCS J3032: Injection, eptinezumab-jjmr, 1 mg

HCPCS Level II code J3032 designates a 1 mg unit of eptinezumab-jjmr, an intravenous monoclonal antibody used for migraine prevention. As an HCPCS Level II injectable drug code, J3032 is used by facilities and billing professionals to report administration of the biologic and to facilitate payment and utilization tracking for outpatient infusion services. Nationally, accurate use of this code supports consistent claims processing and monitoring of biologic migraine therapies as their use grows.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise profile of the code’s clinical context and service setting, a summary of typical payer considerations and common billing modifiers, and references to benchmarking and policy topics relevant to outpatient administration of high-cost biologics. The publication highlights billing and coding clarity, common places of service for infusion, and where stakeholders should confirm payer-specific coverage criteria, prior authorization requirements, and billing unit conventions.

Content is intended to orient clinicians, billing staff, and policy analysts to the primary purpose of J3032, common operational settings for administration, and the payer landscape relevant to national billing and reimbursement practices.

Billing Code Overview

HCPCS Level II code J3032 represents an injectable formulation identified as eptinezumab-jjmr, 1 mg. This code denotes a billed unit of the monoclonal antibody product used for intravenous administration in the preventive treatment of migraine disorders.

Service Type: Injection (intravenous biologic therapy)

Typical Site of Service: Outpatient infusion center or outpatient hospital/clinic setting

Clinical Context

A typical patient is an adult with a diagnosis of chronic migraine who presents to an infusion center or outpatient clinic for administration of an intravenous or intravenous/infusion-related biologic therapy. The clinician orders J3032 (injection, eptinezumab-jjmr, 1 mg) for parenteral administration as a preventive migraine therapy. The patient arrives for a scheduled visit after prior authorization is obtained when required by the payer. Clinical workflow includes verification of identity and consent, allergy review, medication reconciliation, baseline vital signs, and assessment of recent migraine frequency and response to prior therapies.

During the visit a registered nurse prepares the dose per prescribing information, performs an IV placement if required (note: eptinezumab is administered intravenously), administers the medication over the required infusion time, and monitors the patient during and after infusion for infusion-related reactions. Post-infusion documentation includes lot number, dose administered, route, start and end times, patient tolerance, and any adverse events. The encounter may include evaluation and management services if an unrelated problem is addressed on the same day.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug or biological amount discarded	When partial vial/unused eptinezumab is discarded and must be reported per payer policy.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Neurology	Neurologists commonly prescribe eptinezumab for migraine prevention.
`2084N0400X`	Allergy & Immunology	Allergists/immunologists may manage biologic therapies and infusion reactions.
`364S00000X`	Nursing — Infusion Therapy	Infusion nurses administer and monitor IV biologic therapies.
`363L00000X`	Anesthesiology Assistants	If anesthesia or sedation is required for infusion tolerance, these providers may be involved.
`352600000X`	Pain Medicine	Pain medicine specialists may treat refractory headache disorders and prescribe preventive biologics.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G43.709`	Migraine without aura, not intractable, without status migrainosus	Represents episodic or chronic migraine for which preventive therapy may be indicated.
`G43.701`	Migraine with aura, not intractable, without status migrainosus	Migraines with aura can be treated with preventive monoclonal antibodies when criteria met.
`G43.901`	Migraine, unspecified, intractable, without status migrainosus	Intractable migraine is a common indication for advanced preventive biologic therapy.
`G43.009`	Migraine, unspecified, not intractable, without status migrainosus	Used when migraine diagnosis is documented but subtype not specified.
`R51`	Headache	Symptom code used when a more specific migraine code is not documented; less specific for payer authorization.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when eptinezumab is administered via IV infusion and the infusion duration fits this time frame for initial hour billing.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary service)	Used when IV infusion extends beyond the initial hour and additional time is billable.
`92950`	Cardiopulmonary resuscitation (CPR), emergency life-saving procedure	Included as a preparedness billing reference; not routinely billed with infusion but relevant if emergency resuscitation occurs.
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs or monitoring prior to or during treatment as clinically indicated.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M level when counseling or medication management is performed on the same day as the infusion.

OpenPayer

Summary & Overview